期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PTEN的表达调控及入核机制 被引量：1

Mechanisms of regulation and nuclear localization of PTEN
原文传递
导出
摘要 抑癌基因磷酸酶与张力蛋白同源物(phosphatase and tensin homolog,PTEN)基因的功能缺失往往会形成多种类型的癌症,它的表达在转录和转录后水平都受到严格的调控。本文对PTEN表达的调控机制以及PTEN的相关核质转运机制进行了综述。 Loss of function ofPTEN, a tumor suppressor gene, usually contributes to the development of many cancers. It appears to be regulated both in transcriptionally and post-transcriptionally. Here we discuss recent progress in the mechanisms of PTEN regulation and entering the nucleus.
作者 邱翔 马中良 金由辛
机构地区 上海大学生命科学学院
出处 《生命的化学》 CAS CSCD 2012年第5期408-412,共5页 Chemistry of Life
基金 上海市自然科学基金项目(11ZR1412200) 国家自然科学基金项目(31170750) 上海市教委分子生理学重点学科资助
关键词 PTEN 转录后 细胞核 调控 PTEN post-transcriptionally nucleus regulation
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

  • 1Marion Peyrou,Lucie Bourgoin,Michelangelo Foti.PTEN in liver diseases and cancer[J].World Journal of Gastroenterology,2010,16(37):4627-4633. 被引量：17
  • 2Fang-Hua Li,Zhuang-Hua Li,Hui-Yan Luo,Miao-Zhen Qiu,Yu-Hong Li,Rui-Hua Xu,State Key Laboratory of Oncology in Southern China,Department of Medical Oncology,Sun YatSen University Cancer Center,Guangzhou 510060,Guangdong Province,China Fang-Hua Li,Department of Medical Oncology,Shengli Oil Field Central Hospital,Dongying 257034,Shandong Province,China Lin Shen,Department of GI Oncology,Peking University School of Oncology,Beijing Cancer Hospital and Institute,Beijing 100142,China Hui-Zhong Zhang,State Key Laboratory of Oncology in Southern China,Department of Pathology,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guangdong Province,China.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J].World Journal of Gastroenterology,2010,16(46):5881-5888. 被引量：9

二级参考文献24

  • 1Folprecht G,Gruenberger T,Bechstein WO,Raab HR,Lordick F,Hartmann JT,Lang H,Frilling A,Stoehlmacher J,Weitz J,Konopke R,Stroszczynski C,Liersch T,Ockert D,Herrmann T,Goekkurt E,Parisi F,K hne CH.Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial. The Lancet Oncology . 2010
  • 2Van Cutsem E,K hne CH,Hitre E,Zaluski J,Chang Chien CR,Makhson A,D‘Haens G,Pintér T,Lim R,Bodoky G,Roh JK,Folprecht G,Ruff P,Stroh C,Tejpar S,Schlichting M,Nippgen J,Rougier P.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine . 2009
  • 3Sartore-Bianchi A,Martini M,Molinari F,Veronese S,Nichelatti M,Artale S,Di Nicolantonio F,Saletti P,De Dosso S,Mazzucchelli L,Frattini M,Siena S,Bardelli A.PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research . 2009
  • 4Loupakis F,Pollina L,Stasi I,Ruzzo A,Scartozzi M,Santini D,Masi G,Graziano F,Cremolini C,Rulli E,Canestrari E,Funel N,Schiavon G,Petrini I,Magnani M,Tonini G,Campani D,Floriani I,Cascinu S,Falcone A.PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology . 2009
  • 5Heinemann V,Stintzing S,Kirchner T,Boeck S,Jung A.Clinical relevance of EGFRand KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treatment Reviews . 2009
  • 6Lièvre A,Bachet JB,Boige V,Cayre A,Le Corre D,Buc E,Ychou M,Bouché O,Landi B,Louvet C,AndréT,Bibeau F,Diebold MD,Rougier P,Ducreux M,Tomasic G,Emile JF,Penault-Llorca F,Laurent-Puig P.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology . 2008
  • 7van Zandwijk N,Mathy A,Boerrigter L,Ruijter H,Tielen I,de Jong D,Baas P,Burgers S,Nederlof P.EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors:retroand prospective observations in non-small-cell lung cancer. Annals of Oncology . 2007
  • 8Cunningham D,Humblet Y,Siena S,Khayat D,Bleiberg H,Santoro A,Bets D,Mueser M,Harstrick A,Verslype C,Chau I,Van Cutsem E.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine . 2004
  • 9Aoki Y,Hosaka S,Tachibana N,Karasawa Y,Kawa S,Kiyosawa K.Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. Pancreas . 2000
  • 10Andreyev, H.J,Norman, A.R,Cunningham, D,Oates, J.R,Clarke, P.A.Kirsten ras mutations in patients with colorectal cancer:the multicenter "RASCAL" study. Journal of the National Cancer Institute . 1998

共引文献24

同被引文献10

引证文献1

二级引证文献9

生命的化学
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部